Racine Jean-Olivier
Known title: Chief Technology OfficerCIK: 0001868039
Associated companies
Transaction History
| OM | ▼ Sell | Open Market | 8,306 | $27K | 5/10/2024 | View on chart |
| OM | ▼ Sell | Open Market | 1,866 | $7K | 2/15/2024 | View on chart |
| OM | ▼ Sell | Open Market | 723 | $3K | 1/16/2024 | View on chart |
| OM | ▲ Buy | Grant | 96,000 | $0 | 1/12/2024 | View on chart |
| OM | ▲ Buy | Grant | 100,000 | $0 | 1/12/2024 | View on chart |
| OM | ▲ Buy | Grant | 4,638 | $0 | 1/12/2024 | View on chart |
| OM | ▼ Sell | Open Market | 3,905 | $21K | 1/8/2024 | View on chart |
| OM | ▼ Sell | Open Market | 790 | $4K | 11/16/2023 | View on chart |
| OM | ▼ Sell | Open Market | 752 | $11K | 8/16/2023 | View on chart |
| OM | ▼ Sell | Open Market | 735 | $15K | 5/16/2023 | View on chart |
| OM | ▼ Sell | Open Market | 297 | $7K | 2/16/2023 | View on chart |
| OM | ▼ Sell | Open Market | 451 | $11K | 2/16/2023 | View on chart |
| OM | ▼ Sell | Open Market | 2,066 | $58K | 1/27/2023 | View on chart |
| OM | ▲ Buy | Grant | 38,834 | $0 | 1/6/2023 | View on chart |
| OM | ▲ Buy | Grant | 2,184 | $0 | 1/6/2023 | View on chart |
| OM | ▼ Sell | Open Market | 292 | $6K | 11/16/2022 | View on chart |
| OM | ▼ Sell | Open Market | 292 | $6K | 8/16/2022 | View on chart |
| OM | ▼ Sell | Open Market | 1,157 | $17K | 6/23/2022 | View on chart |
| OM | ▲ Buy | Grant | 21,489 | $0 | 1/26/2022 | View on chart |
| OM | ▲ Buy | Grant | 1,209 | $0 | 1/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Hims & Hers news mentioned in broader market context
Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.
Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.